Adaptive Biotechnologies (FRA:1HM) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1HM Adaptive Biotechnologies Corp FRA:1HM
68 GF Score
Price €20.00
GF Value €9.07
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies FFO per Share?

FFO per Share only applies to REITs.

FRA:1HM
68GF Score
Adaptive Biotechnologies Corp FRA:1HM
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Adaptive Biotechnologies (FRA:1HM) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of €20.00 is trading 120.5% above its estimated GF Value™ of €9.07. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for FRA:1HM:

  • FFO per Share:
  • GF Value™: €9.07 vs. price of €20.00 (120.5% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the FRA:1HM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Other Exchanges ADPT:USA
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
68GF Score

Get the complete analysis for FRA:1HM

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.00
Price
€9.07
GF Value